SEC Form 4 · accession 0000905148-26-003033
Acrivon Therapeutics, Inc. · ACRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Derek DiRocco
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001781174
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $1.52 | Jun 17, 2026 | A | 20,275 | A | — | Jun 16, 2036 | Common Stock | 20,275 | 20,275 | D |
Explanation of responses
- F1The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
- F2Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.